Low-FODMAP vs Gluten-Free Diet in Irritable Bowel Syndrome
LF-GFD
Comparison of the Efficacy of Low-FODMAP and Gluten-Free Diets in the Dietary Management of Irritable Bowel Syndrome in a Turkish Population: A Prospective, Controlled, Parallel-Group Clinical Trial
1 other identifier
interventional
70
1 country
1
Brief Summary
Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain and irregular bowel habits. Dietary interventions, particularly low-FODMAP and gluten-free diets, have gained increasing interest in IBS management. However, comparative data on these two approaches remain limited across different populations, including the Turkish population. This study was designed to compare the effectiveness of a 4-week low-FODMAP diet versus a gluten-free diet on gastrointestinal symptoms in Turkish patients with IBS. A total of 70 patients diagnosed with IBS according to Rome IV criteria were enrolled in this prospective, controlled, parallel-group clinical trial. Patients were sequentially assigned to either the low-FODMAP group (n=35) or the gluten-free diet group (n=35). Both dietary interventions were implemented over 4 weeks under the guidance of an experienced dietitian, with weekly telephone follow-ups to monitor dietary compliance. Gastrointestinal symptoms were evaluated at baseline and at the end of the intervention using the Gastrointestinal Symptom Rating Scale (GSRS).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 24, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 20, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
July 25, 2026
CompletedFirst Submitted
Initial submission to the registry
August 25, 2026
CompletedFirst Posted
Study publicly available on registry
September 2, 2026
CompletedSeptember 2, 2026
August 1, 2026
7 months
August 25, 2026
August 28, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Total GSRS Score
Change in the total Gastrointestinal Symptom Rating Scale (GSRS) score from baseline to 4 weeks. The GSRS is a 15-item scale with total scores ranging from 15 to 105. Higher scores indicate more severe gastrointestinal symptoms.
Baseline and 4 weeks
Secondary Outcomes (5)
Change in GSRS Diarrhea Subscale Score
Baseline and 4 weeks
Change in GSRS Indigestion Subscale Score
Baseline and 4 weeks
Change in GSRS Constipation Subscale Score
Baseline and 4 weeks
Change in GSRS Abdominal Pain Subscale Score
Baseline and 4 weeks
Change in GSRS Reflux Subscale Score
Baseline and 4 weeks
Study Arms (2)
Low-FODMAP Diet Group
EXPERIMENTALParticipants followed a low-FODMAP diet for 4 weeks under the guidance of an experienced dietitian.
Gluten-Free Diet Group
EXPERIMENTALParticipants followed a strict gluten-free diet for 4 weeks under the guidance of an experienced dietitian.
Interventions
Participants were instructed to exclude gluten-containing grains (wheat, barley, rye) and their derivatives (bread, pasta, pastries), and to consume naturally gluten-free foods (rice, corn, potatoes, meat, vegetables, fruits). The diet was applied for 4 weeks.
Participants were instructed to limit foods high in FODMAPs (onions, garlic, pulses, certain fruits and vegetables, wheat products) and to consume low-FODMAP alternatives (rice, oats, potatoes, carrots, bananas). The diet was applied for 4 weeks.
Eligibility Criteria
You may qualify if:
- Diagnosed with Irritable Bowel Syndrome (IBS) according to the Rome IV diagnostic criteria
- Aged between 18 and 65 years
- Literate
- Signed the informed consent form
You may not qualify if:
- Psychiatric or neurological condition affecting cooperation (dementia, psychosis, etc.)
- Chronic condition (celiac disease, inflammatory bowel disease, diabetes, chronic kidney failure, liver failure, malignancy)
- Regular use of medication for IBS symptoms (antispasmodics, loperamide, laxatives, antidepressants, etc.)
- Eating disorder (anorexia nervosa, bulimia nervosa, etc.)
- Malabsorption syndrome preventing adherence to the diet
- Pregnancy or breastfeeding
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ertuğrul Çoruhlead
Study Sites (1)
Yıldızkent Family Health Center
Erzurum, 25080, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ertuğrul Çoruh, MD
Yıldızkent Family Health Center, Palandöken District Health Directorate, Erzurum, Turkey
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Family Physician
Study Record Dates
First Submitted
August 25, 2026
First Posted
September 2, 2026
Study Start
December 24, 2025
Primary Completion
July 20, 2026
Study Completion
July 25, 2026
Last Updated
September 2, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will not share